Earli was founded by Dr. Sam Gambhir, Cyriac Roeding, Dr. David Suhy in 2018.

Who are Earli's investors?

Earli's investors include Andreessen Horowitz, Breyer Capital, Han River Partners, Menlo Ventures, DFJ, MBX Capital.

How much funding has Earli raised?

Earli has disclosed $40M raised across 1 round.

Where is Earli headquartered?

Earli is headquartered in South San Francisco, US.

Earli

South San Francisco, US · Founded 2018 · Delaware corporation · 37 employees on LinkedIn · 6 known investors

Earli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells. The company focuses on oncology diagnostics and therapeutics for cancer patients.

AI & Machine Learning Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Earli was founded in 2018 by Dr. Sam Gambhir, Cyriac Roeding, and Dr. David Suhy.

Dr. Sam GambhirFounder

Cyriac RoedinginCo-founder

Dr. David SuhyCo-founder & Chief Scientific Officer

Board

Justin Kao in 𝕏Board directorPartner at DFJ

Jorge Conde in 𝕏Board directorGeneral Partner at Andreessen Horowitz

Investors · 6

Andreessen HorowitzMenlo Park · $500K – $50Mvia Jorge Conde · board

Breyer CapitalAustin · $500K – $10M

Han River PartnersMenlo Park

Menlo VenturesSan Francisco · $1M – $20M

DFJreportedSan Mateovia Justin Kao · board

MBX CapitalreportedClaymont · $250K – $2.5M

Reported raises · per SEC filings

Form D private placements

$40M disclosed across 1 round · 2021

▶$40MraisedJan 2021 · 20 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Justin KaoDirector
Jorge CondeDirector
Cyriac RoedingExecutive Officer, Director
David SuhyExecutive Officer, Director

Offering amount: $40M
Amount sold: $40M
First sale: Jan 2021
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Eli Lilly17 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Intellia Therapeutics9 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

Companies competing with Earli for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Earli do?: Earli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells. The company focuses on oncology diagnostics and therapeutics for cancer patients.
Who founded Earli?: Earli was founded by Dr. Sam Gambhir, Cyriac Roeding, Dr. David Suhy in 2018.
Who are Earli's investors?: Earli's investors include Andreessen Horowitz, Breyer Capital, Han River Partners, Menlo Ventures, DFJ, MBX Capital.
How much funding has Earli raised?: Earli has disclosed $40M raised across 1 round.
Where is Earli headquartered?: Earli is headquartered in South San Francisco, US.